ChromaDex (NASDAQ: CDXC) and Advaxis (NASDAQ:ADXS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings and institutional ownership.

Volatility & Risk

ChromaDex has a beta of 1.12, indicating that its share price is 12% more volatile than the S&P 500. Comparatively, Advaxis has a beta of 1.98, indicating that its share price is 98% more volatile than the S&P 500.

Earnings and Valuation

This table compares ChromaDex and Advaxis’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
ChromaDex $26.81 million 11.97 -$2.92 million ($0.14) -47.57
Advaxis $3.99 million 32.32 -$73.55 million ($2.29) -1.37

ChromaDex has higher revenue and earnings than Advaxis. ChromaDex is trading at a lower price-to-earnings ratio than Advaxis, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations and price targets for ChromaDex and Advaxis, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ChromaDex 0 0 3 0 3.00
Advaxis 0 0 2 0 3.00

ChromaDex presently has a consensus target price of $6.33, suggesting a potential downside of 4.90%. Advaxis has a consensus target price of $21.00, suggesting a potential upside of 568.79%. Given Advaxis’ higher possible upside, analysts clearly believe Advaxis is more favorable than ChromaDex.

Insider & Institutional Ownership

7.6% of ChromaDex shares are held by institutional investors. Comparatively, 44.1% of Advaxis shares are held by institutional investors. 11.6% of ChromaDex shares are held by insiders. Comparatively, 7.2% of Advaxis shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.


This table compares ChromaDex and Advaxis’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ChromaDex -52.94% -43.46% -34.58%
Advaxis -655.66% -93.54% -64.49%


ChromaDex beats Advaxis on 8 of the 12 factors compared between the two stocks.

About ChromaDex

Chromadex Corporation and its subsidiaries ChromaDex, Inc., ChromaDex Analytics, Inc. and Spherix Consulting, Inc. provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. The Company operates through three segments: Ingredients, which develops, supplies and commercializes ingredient technologies; Core standards and contract services, which supplies phytochemical reference standards, which are small quantities of plant-based compounds used to research an array of attributes, reference materials and related contract services, and Scientific and regulatory consulting, which provides scientific and regulatory consulting to the clients in the food, supplement and pharmaceutical industries to manage health and regulatory risks.

About Advaxis

Advaxis, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-LLO strains integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T-cells to eliminate tumors. Axalimogene filolisbac is its lead Lm-LLO immunotherapy product candidate for the treatment of Human Papilloma Virus-associated cancers. ADXS-PSA is its Lm-LLO immunotherapy product candidate that targets the Prostate Specific Antigen (PSA) associated with prostate cancer.

Receive News & Stock Ratings for ChromaDex Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChromaDex Co. and related stocks with our FREE daily email newsletter.